SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:umu-81310"
 

Search: onr:"swepub:oai:DiVA.org:umu-81310" > Effects of the Sele...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Tannous, Bakhos A. (author)

Effects of the Selective MPS1 Inhibitor MPS1-IN-3 on Glioblastoma Sensitivity to Antimitotic Drugs

  • Article/chapterEnglish2013

Publisher, publication year, extent ...

  • 2013-08-12
  • Oxford University Press,2013
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:umu-81310
  • https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-81310URI
  • https://doi.org/10.1093/jnci/djt168DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Background Glioblastomas exhibit a high level of chemotherapeutic resistance, including to the antimitotic agents vincristine and taxol. During the mitotic agent-induced arrest, glioblastoma cells are able to perform damage-control and self-repair to continue proliferation. Monopolar spindle 1 (MPS1/TTK) is a checkpoint kinase and a gatekeeper of the mitotic arrest.Methods We used glioblastoma cells to determine the expression of MPS1 and to determine the effects of MPS1 inhibition on mitotic errors and cell viability in combination with vincristine and taxol. The effect of MPS1 inhibition was assessed in different orthotopic glioblastoma mouse models (n = 3-7 mice/group). MPS1 expression levels were examined in relation to patient survival.Results Using publicly available gene expression data, we determined that MPS1 overexpression corresponds positively with tumor grade and negatively with patient survival (two-sided t test, P < .001). Patients with high MPS1 expression (n = 203) had a median and mean survival of 487 and 913 days (95% confidence intervals [CI] = 751 to 1075), respectively, and a 2-year survival rate of 35%, whereas patients with intermediate MPS1 expression (n = 140) had a median and mean survival of 858 and 1183 days (95% CI = 1177 to 1189), respectively, and a 2-year survival rate of 56%. We demonstrate that MPS1 inhibition by RNAi results in sensitization to antimitotic agents. We developed a selective small-molecule inhibitor of MPS1, MPS1-IN-3, which caused mitotic aberrancies in glioblastoma cells and, in combination with vincristine, induced mitotic checkpoint override, increased aneuploidy, and augmented cell death. MPS1-IN-3 sensitizes glioblastoma cells to vincristine in orthotopic mouse models (two-sided log-rank test, P < .01), resulting in prolonged survival without toxicity.Conclusions Our results collectively demonstrate that MPS1, a putative therapeutic target in glioblastoma, can be selectively inhibited by MPS1-IN-3 sensitizing glioblastoma cells to antimitotic drugs.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Kerami, Mariam (author)
  • Van der Stoop, Petra M. (author)
  • Kwiatkowski, Nicholas (author)
  • Wang, Jinhua (author)
  • Zhou, Wenjun (author)
  • Kessler, Almuth F. (author)
  • Lewandrowski, Grant (author)
  • Hiddingh, Lotte (author)
  • Sol, Nik (author)
  • Lagerweij, Tonny (author)
  • Wedekind, Laurine (author)
  • Niers, Johanna M. (author)
  • Barazas, Marco (author)
  • Nilsson, R. Jonas A.Umeå universitet,Onkologi(Swepub:umu)joni0002 (author)
  • Geerts, Dirk (author)
  • Hamer, Philip C. De Witt (author)
  • Hagemann, Carsten (author)
  • Vandertop, W. Peter (author)
  • Van Tellingen, Olaf (author)
  • Noske, David P. (author)
  • Gray, Nathanael S. (author)
  • Wuerdinger, Thomas (author)
  • Umeå universitetOnkologi (creator_code:org_t)

Related titles

  • In:Journal of the National Cancer Institute: Oxford University Press105:17, s. 1322-13310027-88741460-2105

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view